Why shareholders are suing Novo Nordisk over next-generation weight-loss drug

Shareholders are suing Novo Nordisk, alleging the company misled them about the clinical trial design for its next-generation obesity drug, CagriSema. A US federal judge has allowed parts of the lawsuit to proceed, specifically claims that Novo was not transparent about the trial's flexible dosing protocol, which led to disappointing results and a significant drop in stock value.

This Wire brief sits within Fusion42's coverage of Drug Discovery. Wire is Fusion42's founder-focused intelligence feed: each story is connected to the funds and startups it names — every one with a live profile on Raise or Scout — so founders can follow the capital and the momentum behind the headline rather than just the headline itself. Wire analysis is one of the live surfaces Arthur reasons over.